<StartOutput><Paragraphs Count="10"><Paragraph id="0"><Sentences Count="4"><Sentence id="0">This is a literature study from Journal of Clinical Pharmacy and Therapeutics, 2014, Vol 39 (3), pages 259-265, entitled, "Sunitinib for metastatic renal cell cancer patients: Observational study highlighting the risk of important drug-drug interactions."<Tokens Count="46"><Token POSTag="DT" id="0">This</Token><Token POSTag="VBZ" id="1">is</Token><Token POSTag="DT" id="2">a</Token><Token POSTag="NN" id="3">literature</Token><Token POSTag="NN" id="4">study</Token><Token POSTag="IN" id="5">from</Token><Token POSTag="NN" id="6">Journal</Token><Token POSTag="IN" id="7">of</Token><Token POSTag="JJ" id="8">Clinical</Token><Token POSTag="NN" id="9">Pharmacy</Token><Token POSTag="CC" id="10">and</Token><Token POSTag="NNS" id="11">Therapeutics</Token><Token POSTag="," id="12">,</Token><Token POSTag="CD" id="13">2014</Token><Token POSTag="," id="14">,</Token><Token POSTag="NN" id="15">Vol</Token><Token POSTag="CD" id="16">39</Token><Token POSTag="-LRB-" id="17">(</Token><Token POSTag="CD" id="18">3</Token><Token POSTag="-RRB-" id="19">)</Token><Token POSTag="," id="20">,</Token><Token POSTag="NNS" id="21">pages</Token><Token POSTag="CD" id="22">259-265</Token><Token POSTag="," id="23">,</Token><Token POSTag="JJ" id="24">entitled</Token><Token POSTag="," id="25">,</Token><Token POSTag="``" id="26">``</Token><Token POSTag="NN" id="27">Sunitinib</Token><Token POSTag="IN" id="28">for</Token><Token POSTag="JJ" id="29">metastatic</Token><Token POSTag="JJ" id="30">renal</Token><Token POSTag="NN" id="31">cell</Token><Token POSTag="NN" id="32">cancer</Token><Token POSTag="NNS" id="33">patients</Token><Token POSTag=":" id="34">:</Token><Token POSTag="JJ" id="35">Observational</Token><Token POSTag="NN" id="36">study</Token><Token POSTag="VBG" id="37">highlighting</Token><Token POSTag="DT" id="38">the</Token><Token POSTag="NN" id="39">risk</Token><Token POSTag="IN" id="40">of</Token><Token POSTag="JJ" id="41">important</Token><Token POSTag="JJ" id="42">drug-drug</Token><Token POSTag="NNS" id="43">interactions</Token><Token POSTag="." id="44">.</Token><Token POSTag="NN" id="45">''</Token></Tokens><ParseTree>(S1 (S (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT a) (NN literature) (NN study)) (PP (IN from) (NP (NP (NN Journal)) (PP (IN of) (NP (NP (JJ Clinical) (NN Pharmacy)) (CC and) (NP (NP (NNS Therapeutics)) (, ,) (NP (CD 2014)) (, ,) (NP (NP (NN Vol) (CD 39)) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-))) (, ,) (NP (NNS pages) (CD 259-265)))))))) (, ,) (ADJP (JJ entitled)) (, ,) (S (`` ``) (NP (NP (NN Sunitinib)) (PP (IN for) (NP (JJ metastatic) (JJ renal) (NN cell) (NN cancer) (NNS patients)))) (: :) (NP (JJ Observational) (NN study)) (VP (VBG highlighting) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ important) (JJ drug-drug) (NNS interactions))))))) (. .)) (NP (NN ''))))</ParseTree></Sentence><Sentence id="1">13 cases have been identified to be created for different patients, similar drugs, and same events.<Tokens Count="19"><Token POSTag="CD" id="0">13</Token><Token POSTag="NNS" id="1">cases</Token><Token POSTag="VBP" id="2">have</Token><Token POSTag="VBN" id="3">been</Token><Token POSTag="VBN" id="4">identified</Token><Token POSTag="TO" id="5">to</Token><Token POSTag="VB" id="6">be</Token><Token POSTag="VBN" id="7">created</Token><Token POSTag="IN" id="8">for</Token><Token POSTag="JJ" id="9">different</Token><Token POSTag="NNS" id="10">patients</Token><Token POSTag="," id="11">,</Token><Token POSTag="JJ" id="12">similar</Token><Token POSTag="NNS" id="13">drugs</Token><Token POSTag="," id="14">,</Token><Token POSTag="CC" id="15">and</Token><Token POSTag="JJ" id="16">same</Token><Token POSTag="NNS" id="17">events</Token><Token POSTag="." id="18">.</Token></Tokens><ParseTree>(S1 (S (S (NP (CD 13) (NNS cases)) (VP (VBP have) (VP (VBN been) (VP (VBN identified) (S (VP (TO to) (VP (VB be) (VP (VBN created) (PP (IN for) (NP (NP (JJ different) (NNS patients)) (, ,) (NP (JJ similar) (NNS drugs)) (, ,) (CC and) (NP (JJ same) (NNS events)))))))))))) (. .)))</ParseTree></Sentence><Sentence id="2">This is 3 of 13 reports.<Tokens Count="7"><Token POSTag="DT" id="0">This</Token><Token POSTag="VBZ" id="1">is</Token><Token POSTag="CD" id="2">3</Token><Token POSTag="IN" id="3">of</Token><Token POSTag="CD" id="4">13</Token><Token POSTag="NNS" id="5">reports</Token><Token POSTag="." id="6">.</Token></Tokens><ParseTree>(S1 (S (S (NP (DT This)) (VP (VBZ is) (NP (NP (CD 3)) (PP (IN of) (NP (CD 13) (NNS reports)))))) (. .)))</ParseTree></Sentence><Sentence id="3">This case captures Patient 10 of Table 4.<Tokens Count="9"><Token POSTag="DT" id="0">This</Token><Token POSTag="NN" id="1">case</Token><Token POSTag="VBZ" id="2">captures</Token><Token POSTag="NN" id="3">Patient</Token><Token POSTag="CD" id="4">10</Token><Token POSTag="IN" id="5">of</Token><Token POSTag="NN" id="6">Table</Token><Token POSTag="CD" id="7">4</Token><Token POSTag="." id="8">.</Token></Tokens><ParseTree>(S1 (S (S (NP (DT This) (NN case)) (VP (VBZ captures) (NP (NP (NN Patient) (CD 10)) (PP (IN of) (NP (NN Table) (CD 4)))))) (. .)))</ParseTree></Sentence></Sentences></Paragraph><Paragraph id="1"><Sentences Count="3"><Sentence id="0">A retrospective analysis of patients treated with sunitinib for metastatic renal cell cancer (mRCC) from 01Oct2007 until 01Oct2011 was performed.<Tokens Count="23"><Token POSTag="DT" id="0">A</Token><Token POSTag="JJ" id="1">retrospective</Token><Token POSTag="NN" id="2">analysis</Token><Token POSTag="IN" id="3">of</Token><Token POSTag="NNS" id="4">patients</Token><Token POSTag="VBN" id="5">treated</Token><Token POSTag="IN" id="6">with</Token><Token POSTag="NN" id="7">sunitinib</Token><Token POSTag="IN" id="8">for</Token><Token POSTag="JJ" id="9">metastatic</Token><Token POSTag="JJ" id="10">renal</Token><Token POSTag="NN" id="11">cell</Token><Token POSTag="NN" id="12">cancer</Token><Token POSTag="-LRB-" id="13">(</Token><Token POSTag="NN" id="14">mRCC</Token><Token POSTag="-RRB-" id="15">)</Token><Token POSTag="IN" id="16">from</Token><Token POSTag="CD" id="17">01Oct2007</Token><Token POSTag="IN" id="18">until</Token><Token POSTag="NN" id="19">01Oct2011</Token><Token POSTag="VBD" id="20">was</Token><Token POSTag="VBN" id="21">performed</Token><Token POSTag="." id="22">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NP (DT A) (JJ retrospective) (NN analysis)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN sunitinib))) (PP (IN for) (NP (NP (NP (JJ metastatic) (JJ renal) (NN cell) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN mRCC)) (-RRB- -RRB-))) (PP (IN from) (NP (NP (CD 01Oct2007)) (PP (IN until) (NP (NN 01Oct2011))))))))))) (VP (VBD was) (VP (VBN performed)))) (. .)))</ParseTree></Sentence><Sentence id="1">Dosage of sunitinib must be decreased in the presence of adverse drug reactions (from grade 3 on Common Terminology Criteria for Adverse Events of the National Cancer Institute, version 3.0) or at lower toxicity levels at patients/physicians decision.<Tokens Count="42"><Token POSTag="NN" id="0">Dosage</Token><Token POSTag="IN" id="1">of</Token><Token POSTag="NN" id="2">sunitinib</Token><Token POSTag="MD" id="3">must</Token><Token POSTag="VB" id="4">be</Token><Token POSTag="VBN" id="5">decreased</Token><Token POSTag="IN" id="6">in</Token><Token POSTag="DT" id="7">the</Token><Token POSTag="NN" id="8">presence</Token><Token POSTag="IN" id="9">of</Token><Token POSTag="JJ" id="10">adverse</Token><Token POSTag="NN" id="11">drug</Token><Token POSTag="NNS" id="12">reactions</Token><Token POSTag="-LRB-" id="13">(</Token><Token POSTag="IN" id="14">from</Token><Token POSTag="NN" id="15">grade</Token><Token POSTag="CD" id="16">3</Token><Token POSTag="IN" id="17">on</Token><Token POSTag="JJ" id="18">Common</Token><Token POSTag="JJ" id="19">Terminology</Token><Token POSTag="NNS" id="20">Criteria</Token><Token POSTag="IN" id="21">for</Token><Token POSTag="JJ" id="22">Adverse</Token><Token POSTag="NNS" id="23">Events</Token><Token POSTag="IN" id="24">of</Token><Token POSTag="DT" id="25">the</Token><Token POSTag="JJ" id="26">National</Token><Token POSTag="NN" id="27">Cancer</Token><Token POSTag="NN" id="28">Institute</Token><Token POSTag="," id="29">,</Token><Token POSTag="NN" id="30">version</Token><Token POSTag="CD" id="31">3.0</Token><Token POSTag="-RRB-" id="32">)</Token><Token POSTag="CC" id="33">or</Token><Token POSTag="IN" id="34">at</Token><Token POSTag="JJR" id="35">lower</Token><Token POSTag="NN" id="36">toxicity</Token><Token POSTag="NNS" id="37">levels</Token><Token POSTag="IN" id="38">at</Token><Token POSTag="NN" id="39">patients/physicians</Token><Token POSTag="NN" id="40">decision</Token><Token POSTag="." id="41">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NP (NN Dosage)) (PP (IN of) (NP (NN sunitinib)))) (VP (MD must) (VP (VB be) (VP (VBN decreased) (PP (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ adverse) (NN drug) (NNS reactions)) (PRN (-LRB- -LRB-) (PP (IN from) (NP (NP (NN grade) (CD 3)) (PP (IN on) (NP (NP (NP (JJ Common) (JJ Terminology) (NNS Criteria)) (PP (IN for) (NP (NP (JJ Adverse) (NNS Events)) (PP (IN of) (NP (DT the) (JJ National) (NN Cancer) (NN Institute)))))) (, ,) (NP (NN version) (CD 3.0)))))) (-RRB- -RRB-)))))) (CC or) (PP (IN at) (NP (NP (JJR lower) (NN toxicity) (NNS levels)) (PP (IN at) (NP (NN patients/physicians) (NN decision)))))))))) (. .)))</ParseTree></Sentence><Sentence id="2">Dosages are decreased in steps of 12.5 mg. Sunitinib treatment must be discontinued in case of progressive disease [Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST criteria)], in case of intolerable toxicity or if patient is no longer willing to take the medication whatever the reason.<Tokens Count="53"><Token POSTag="NNS" id="0">Dosages</Token><Token POSTag="VBP" id="1">are</Token><Token POSTag="VBN" id="2">decreased</Token><Token POSTag="IN" id="3">in</Token><Token POSTag="NNS" id="4">steps</Token><Token POSTag="IN" id="5">of</Token><Token POSTag="CD" id="6">12.5</Token><Token POSTag="NN" id="7">mg.</Token><Token POSTag="NN" id="8">Sunitinib</Token><Token POSTag="NN" id="9">treatment</Token><Token POSTag="MD" id="10">must</Token><Token POSTag="VB" id="11">be</Token><Token POSTag="VBN" id="12">discontinued</Token><Token POSTag="IN" id="13">in</Token><Token POSTag="NN" id="14">case</Token><Token POSTag="IN" id="15">of</Token><Token POSTag="JJ" id="16">progressive</Token><Token POSTag="NN" id="17">disease</Token><Token POSTag="-LRB-" id="18">[</Token><Token POSTag="NN" id="19">Response</Token><Token POSTag="NN" id="20">Evaluation</Token><Token POSTag="NNS" id="21">Criteria</Token><Token POSTag="IN" id="22">In</Token><Token POSTag="JJ" id="23">Solid</Token><Token POSTag="NNS" id="24">Tumors</Token><Token POSTag="NN" id="25">version</Token><Token POSTag="CD" id="26">1.1</Token><Token POSTag="-LRB-" id="27">(</Token><Token POSTag="NN" id="28">RECIST</Token><Token POSTag="NNS" id="29">criteria</Token><Token POSTag="-RRB-" id="30">)</Token><Token POSTag="-RRB-" id="31">]</Token><Token POSTag="," id="32">,</Token><Token POSTag="IN" id="33">in</Token><Token POSTag="NN" id="34">case</Token><Token POSTag="IN" id="35">of</Token><Token POSTag="JJ" id="36">intolerable</Token><Token POSTag="NN" id="37">toxicity</Token><Token POSTag="CC" id="38">or</Token><Token POSTag="IN" id="39">if</Token><Token POSTag="NN" id="40">patient</Token><Token POSTag="VBZ" id="41">is</Token><Token POSTag="RB" id="42">no</Token><Token POSTag="RBR" id="43">longer</Token><Token POSTag="VBG" id="44">willing</Token><Token POSTag="TO" id="45">to</Token><Token POSTag="VB" id="46">take</Token><Token POSTag="DT" id="47">the</Token><Token POSTag="NN" id="48">medication</Token><Token POSTag="WDT" id="49">whatever</Token><Token POSTag="DT" id="50">the</Token><Token POSTag="NN" id="51">reason</Token><Token POSTag="." id="52">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NNS Dosages)) (VP (VBP are) (VP (VBN decreased) (SBAR (SBAR (IN in) (S (NP (NP (NNS steps)) (PP (IN of) (NP (ADJP (CD 12.5) (NN mg.)) (NN Sunitinib) (NN treatment)))) (VP (MD must) (VP (VB be) (VP (VBN discontinued) (PP (IN in) (NP (NP (NN case)) (PP (IN of) (NP (NP (JJ progressive) (NN disease)) (PRN (-LRB- -LSB-) (NP (NP (NP (NN Response) (NN Evaluation) (NNS Criteria)) (PP (IN In) (NP (JJ Solid) (NNS Tumors)))) (NP (NP (NN version) (CD 1.1)) (PRN (-LRB- -LRB-) (NP (NN RECIST) (NNS criteria)) (-RRB- -RRB-)))) (-RRB- -RSB-)))))) (, ,) (PP (IN in) (NP (NP (NN case)) (PP (IN of) (NP (JJ intolerable) (NN toxicity)))))))))) (CC or) (SBAR (IN if) (S (NP (NN patient)) (VP (VBZ is) (ADVP (RB no) (RBR longer)) (VP (VBG willing) (S (VP (TO to) (VP (VB take) (NP (NP (DT the) (NN medication)) (SBAR (WHNP (WDT whatever)) (S (VP (DT the) (NN reason)))))))))))))))) (. .)))</ParseTree></Sentence></Sentences></Paragraph><Paragraph id="2"><Sentences Count="5"><Sentence id="0">Medication was screened for possible drug-drug interactions.<Tokens Count="8"><Token POSTag="NN" id="0">Medication</Token><Token POSTag="VBD" id="1">was</Token><Token POSTag="VBN" id="2">screened</Token><Token POSTag="IN" id="3">for</Token><Token POSTag="JJ" id="4">possible</Token><Token POSTag="JJ" id="5">drug-drug</Token><Token POSTag="NNS" id="6">interactions</Token><Token POSTag="." id="7">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NN Medication)) (VP (VBD was) (VP (VBN screened) (PP (IN for) (NP (JJ possible) (JJ drug-drug) (NNS interactions)))))) (. .)))</ParseTree></Sentence><Sentence id="1">Interactions were divided into two main categories: pharmacokinetic or pharmacodynamic, with the major pharmacokinetic interactions being co-administration of potent strong CYP3A4 inhibitors (e.g.<Tokens Count="27"><Token POSTag="NNS" id="0">Interactions</Token><Token POSTag="VBD" id="1">were</Token><Token POSTag="VBN" id="2">divided</Token><Token POSTag="IN" id="3">into</Token><Token POSTag="CD" id="4">two</Token><Token POSTag="JJ" id="5">main</Token><Token POSTag="NNS" id="6">categories</Token><Token POSTag=":" id="7">:</Token><Token POSTag="JJ" id="8">pharmacokinetic</Token><Token POSTag="CC" id="9">or</Token><Token POSTag="JJ" id="10">pharmacodynamic</Token><Token POSTag="," id="11">,</Token><Token POSTag="IN" id="12">with</Token><Token POSTag="DT" id="13">the</Token><Token POSTag="JJ" id="14">major</Token><Token POSTag="JJ" id="15">pharmacokinetic</Token><Token POSTag="NNS" id="16">interactions</Token><Token POSTag="VBG" id="17">being</Token><Token POSTag="NN" id="18">co-administration</Token><Token POSTag="IN" id="19">of</Token><Token POSTag="JJ" id="20">potent</Token><Token POSTag="JJ" id="21">strong</Token><Token POSTag="NN" id="22">CYP3A4</Token><Token POSTag="NNS" id="23">inhibitors</Token><Token POSTag="-LRB-" id="24">(</Token><Token POSTag="NN" id="25">e.g</Token><Token POSTag="." id="26">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NNS Interactions)) (VP (VBD were) (VP (VBN divided) (PP (IN into) (NP (NP (CD two) (JJ main) (NNS categories)) (: :) (ADJP (ADJP (JJ pharmacokinetic)) (CC or) (ADJP (JJ pharmacodynamic))))) (, ,) (PP (IN with) (S (NP (DT the) (JJ major) (JJ pharmacokinetic) (NNS interactions)) (VP (VBG being) (NP (NP (NN co-administration)) (PP (IN of) (NP (NP (JJ potent) (JJ strong) (NN CYP3A4) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NN e.g)))))))))))) (. .)))</ParseTree></Sentence><Sentence id="2">ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, telithromycin and voriconazole) or potent strong CYP3A4 inducers (e.g.<Tokens Count="26"><Token POSTag="NN" id="0">ketoconazole</Token><Token POSTag="," id="1">,</Token><Token POSTag="NN" id="2">itraconazole</Token><Token POSTag="," id="3">,</Token><Token POSTag="NN" id="4">clarithromycin</Token><Token POSTag="," id="5">,</Token><Token POSTag="NN" id="6">atazanavir</Token><Token POSTag="," id="7">,</Token><Token POSTag="NN" id="8">indinavir</Token><Token POSTag="," id="9">,</Token><Token POSTag="NN" id="10">nefazodone</Token><Token POSTag="," id="11">,</Token><Token POSTag="NN" id="12">nelfinavir</Token><Token POSTag="," id="13">,</Token><Token POSTag="NN" id="14">telithromycin</Token><Token POSTag="CC" id="15">and</Token><Token POSTag="NN" id="16">voriconazole</Token><Token POSTag="-RRB-" id="17">)</Token><Token POSTag="CC" id="18">or</Token><Token POSTag="JJ" id="19">potent</Token><Token POSTag="JJ" id="20">strong</Token><Token POSTag="NN" id="21">CYP3A4</Token><Token POSTag="NNS" id="22">inducers</Token><Token POSTag="-LRB-" id="23">(</Token><Token POSTag="NN" id="24">e.g</Token><Token POSTag="." id="25">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NP (NP (NN ketoconazole)) (, ,) (NP (NN itraconazole)) (, ,) (NP (NN clarithromycin)) (, ,) (NP (NN atazanavir)) (, ,) (NP (NN indinavir)) (, ,) (NP (NN nefazodone)) (, ,) (NP (NN nelfinavir)) (, ,) (NP (NN telithromycin)) (CC and) (NP (NN voriconazole)) (-RRB- -RRB-)) (CC or) (NP (NP (JJ potent) (JJ strong) (NN CYP3A4) (NNS inducers)) (PRN (-LRB- -LRB-) (NP (NN e.g)))))) (. .)))</ParseTree></Sentence><Sentence id="3">dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, St John's Worth) or other PgP (P-glycoprotein) substrates.<Tokens Count="23"><Token POSTag="NN" id="0">dexamethasone</Token><Token POSTag="," id="1">,</Token><Token POSTag="NN" id="2">phenytoin</Token><Token POSTag="," id="3">,</Token><Token POSTag="NN" id="4">carbamazepine</Token><Token POSTag="," id="5">,</Token><Token POSTag="NN" id="6">rifampicin</Token><Token POSTag="," id="7">,</Token><Token POSTag="NN" id="8">phenobarbital</Token><Token POSTag="," id="9">,</Token><Token POSTag="JJ" id="10">St</Token><Token POSTag="NN" id="11">John</Token><Token POSTag="POS" id="12">'s</Token><Token POSTag="NN" id="13">Worth</Token><Token POSTag="-RRB-" id="14">)</Token><Token POSTag="CC" id="15">or</Token><Token POSTag="JJ" id="16">other</Token><Token POSTag="NN" id="17">PgP</Token><Token POSTag="-LRB-" id="18">(</Token><Token POSTag="NN" id="19">P-glycoprotein</Token><Token POSTag="-RRB-" id="20">)</Token><Token POSTag="NNS" id="21">substrates</Token><Token POSTag="." id="22">.</Token></Tokens><ParseTree>(S1 (S (NP (NP (NN dexamethasone)) (, ,) (NP (NN phenytoin)) (, ,) (NP (NN carbamazepine)) (, ,) (NP (NN rifampicin)) (, ,) (NP (NN phenobarbital)) (, ,) (NP (JJ St) (NN John) (POS 's) (NN Worth) (-RRB- -RRB-)) (CC or) (NP (JJ other) (NN PgP) (-LRB- -LRB-) (NN P-glycoprotein) (-RRB- -RRB-) (NNS substrates)) (. .))))</ParseTree></Sentence><Sentence id="4">The major pharmacodynamic interaction comprises the risk of QT prolongation. <Tokens Count="11"><Token POSTag="DT" id="0">The</Token><Token POSTag="JJ" id="1">major</Token><Token POSTag="JJ" id="2">pharmacodynamic</Token><Token POSTag="NN" id="3">interaction</Token><Token POSTag="VBZ" id="4">comprises</Token><Token POSTag="DT" id="5">the</Token><Token POSTag="NN" id="6">risk</Token><Token POSTag="IN" id="7">of</Token><Token POSTag="NN" id="8">QT</Token><Token POSTag="NN" id="9">prolongation</Token><Token POSTag="." id="10">.</Token></Tokens><ParseTree>(S1 (S (S (NP (DT The) (JJ major) (JJ pharmacodynamic) (NN interaction)) (VP (VBZ comprises) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN QT) (NN prolongation)))))) (. .)))</ParseTree></Sentence></Sentences></Paragraph><Paragraph id="3"><Sentences Count="1"><Sentence id="0">Data from 36 patients with metastatic renal cell cancer treated with sunitinib were analyzed. <Tokens Count="15"><Token POSTag="NNS" id="0">Data</Token><Token POSTag="IN" id="1">from</Token><Token POSTag="CD" id="2">36</Token><Token POSTag="NNS" id="3">patients</Token><Token POSTag="IN" id="4">with</Token><Token POSTag="JJ" id="5">metastatic</Token><Token POSTag="JJ" id="6">renal</Token><Token POSTag="NN" id="7">cell</Token><Token POSTag="NN" id="8">cancer</Token><Token POSTag="VBN" id="9">treated</Token><Token POSTag="IN" id="10">with</Token><Token POSTag="NN" id="11">sunitinib</Token><Token POSTag="VBD" id="12">were</Token><Token POSTag="VBN" id="13">analyzed</Token><Token POSTag="." id="14">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NP (NNS Data)) (PP (IN from) (NP (NP (CD 36) (NNS patients)) (PP (IN with) (NP (JJ metastatic) (JJ renal) (NN cell) (NN cancer))) (VP (VBN treated) (PP (IN with) (NP (NN sunitinib))))))) (VP (VBD were) (VP (VBN analyzed)))) (. .)))</ParseTree></Sentence></Sentences></Paragraph><Paragraph id="4"><Sentences Count="12"><Sentence id="0">First-line patients Sixty-one percentage of our patients (n = 22) received sunitinib as a first-line treatment, whereas 39% (n = 14) received sunitinib from second line on.<Tokens Count="34"><Token POSTag="NN" id="0">First-line</Token><Token POSTag="NNS" id="1">patients</Token><Token POSTag="NN" id="2">Sixty-one</Token><Token POSTag="NN" id="3">percentage</Token><Token POSTag="IN" id="4">of</Token><Token POSTag="PRP$" id="5">our</Token><Token POSTag="NNS" id="6">patients</Token><Token POSTag="-LRB-" id="7">(</Token><Token POSTag="NN" id="8">n</Token><Token POSTag="JJ" id="9">=</Token><Token POSTag="CD" id="10">22</Token><Token POSTag="-RRB-" id="11">)</Token><Token POSTag="VBD" id="12">received</Token><Token POSTag="NN" id="13">sunitinib</Token><Token POSTag="IN" id="14">as</Token><Token POSTag="DT" id="15">a</Token><Token POSTag="JJ" id="16">first-line</Token><Token POSTag="NN" id="17">treatment</Token><Token POSTag="," id="18">,</Token><Token POSTag="IN" id="19">whereas</Token><Token POSTag="CD" id="20">39</Token><Token POSTag="NN" id="21">%</Token><Token POSTag="-LRB-" id="22">(</Token><Token POSTag="NN" id="23">n</Token><Token POSTag="JJ" id="24">=</Token><Token POSTag="CD" id="25">14</Token><Token POSTag="-RRB-" id="26">)</Token><Token POSTag="VBD" id="27">received</Token><Token POSTag="NN" id="28">sunitinib</Token><Token POSTag="IN" id="29">from</Token><Token POSTag="JJ" id="30">second</Token><Token POSTag="NN" id="31">line</Token><Token POSTag="IN" id="32">on</Token><Token POSTag="." id="33">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NP (NN First-line) (NNS patients) (NN Sixty-one) (NN percentage)) (PP (IN of) (NP (NP (PRP$ our) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 22)) (-RRB- -RRB-))))) (VP (VBD received) (NP (NN sunitinib)) (PP (IN as) (NP (DT a) (JJ first-line) (NN treatment))))) (, ,) (IN whereas) (S (NP (NP (CD 39) (NN %)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 14)) (-RRB- -RRB-))) (VP (VBD received) (NP (NP (NN sunitinib)) (PP (IN from) (NP (JJ second) (NN line))) (PP (IN on))))) (. .)))</ParseTree></Sentence><Sentence id="1">Concerning patients treated with sunitinib in first line (n = 22), 12 patients started with a full starting dose of 50 mg daily, 4/6 weeks (55%).<Tokens Count="34"><Token POSTag="VBG" id="0">Concerning</Token><Token POSTag="NNS" id="1">patients</Token><Token POSTag="VBN" id="2">treated</Token><Token POSTag="IN" id="3">with</Token><Token POSTag="NN" id="4">sunitinib</Token><Token POSTag="IN" id="5">in</Token><Token POSTag="JJ" id="6">first</Token><Token POSTag="NN" id="7">line</Token><Token POSTag="-LRB-" id="8">(</Token><Token POSTag="NN" id="9">n</Token><Token POSTag="JJ" id="10">=</Token><Token POSTag="CD" id="11">22</Token><Token POSTag="-RRB-" id="12">)</Token><Token POSTag="," id="13">,</Token><Token POSTag="CD" id="14">12</Token><Token POSTag="NNS" id="15">patients</Token><Token POSTag="VBD" id="16">started</Token><Token POSTag="IN" id="17">with</Token><Token POSTag="DT" id="18">a</Token><Token POSTag="JJ" id="19">full</Token><Token POSTag="VBG" id="20">starting</Token><Token POSTag="NN" id="21">dose</Token><Token POSTag="IN" id="22">of</Token><Token POSTag="CD" id="23">50</Token><Token POSTag="NN" id="24">mg</Token><Token POSTag="RB" id="25">daily</Token><Token POSTag="," id="26">,</Token><Token POSTag="CD" id="27">4/6</Token><Token POSTag="NNS" id="28">weeks</Token><Token POSTag="-LRB-" id="29">(</Token><Token POSTag="CD" id="30">55</Token><Token POSTag="NN" id="31">%</Token><Token POSTag="-RRB-" id="32">)</Token><Token POSTag="." id="33">.</Token></Tokens><ParseTree>(S1 (S (S (PP (VBG Concerning) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NN sunitinib)) (PP (IN in) (NP (NP (JJ first) (NN line)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 22)) (-RRB- -RRB-))))))))) (, ,) (NP (CD 12) (NNS patients)) (VP (VBD started) (PP (IN with) (NP (NP (DT a) (JJ full) (VBG starting) (NN dose)) (PP (IN of) (NP (NP (CD 50) (NN mg)) (ADVP (RB daily)))))) (, ,) (NP (NP (CD 4/6) (NNS weeks)) (PRN (-LRB- -LRB-) (NP (CD 55) (NN %)) (-RRB- -RRB-))))) (. .)))</ParseTree></Sentence><Sentence id="2">The mean age of these 12 patients was 57.4 years (range 45-70 years), and the mean number of comorbidities was 1.5 (range 1-3 comorbidities).<Tokens Count="30"><Token POSTag="DT" id="0">The</Token><Token POSTag="JJ" id="1">mean</Token><Token POSTag="NN" id="2">age</Token><Token POSTag="IN" id="3">of</Token><Token POSTag="DT" id="4">these</Token><Token POSTag="CD" id="5">12</Token><Token POSTag="NNS" id="6">patients</Token><Token POSTag="VBD" id="7">was</Token><Token POSTag="CD" id="8">57.4</Token><Token POSTag="NNS" id="9">years</Token><Token POSTag="-LRB-" id="10">(</Token><Token POSTag="NN" id="11">range</Token><Token POSTag="NN" id="12">45-70</Token><Token POSTag="NNS" id="13">years</Token><Token POSTag="-RRB-" id="14">)</Token><Token POSTag="," id="15">,</Token><Token POSTag="CC" id="16">and</Token><Token POSTag="DT" id="17">the</Token><Token POSTag="NN" id="18">mean</Token><Token POSTag="NN" id="19">number</Token><Token POSTag="IN" id="20">of</Token><Token POSTag="NNS" id="21">comorbidities</Token><Token POSTag="VBD" id="22">was</Token><Token POSTag="CD" id="23">1.5</Token><Token POSTag="-LRB-" id="24">(</Token><Token POSTag="NN" id="25">range</Token><Token POSTag="CD" id="26">1-3</Token><Token POSTag="NNS" id="27">comorbidities</Token><Token POSTag="-RRB-" id="28">)</Token><Token POSTag="." id="29">.</Token></Tokens><ParseTree>(S1 (S (S (S (NP (NP (DT The) (JJ mean) (NN age)) (PP (IN of) (NP (DT these) (CD 12) (NNS patients)))) (VP (VBD was) (NP (NP (CD 57.4) (NNS years)) (PRN (-LRB- -LRB-) (NP (NN range) (NN 45-70) (NNS years)) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (NP (DT the) (NN mean) (NN number)) (PP (IN of) (NP (NNS comorbidities)))) (VP (VBD was) (NP (NP (CD 1.5)) (PRN (-LRB- -LRB-) (NP (NN range) (CD 1-3) (NNS comorbidities)) (-RRB- -RRB-)))))) (. .)))</ParseTree></Sentence><Sentence id="3">Seven of those patients needed dose reductions afterwards due to adverse drug reactions.<Tokens Count="14"><Token POSTag="CD" id="0">Seven</Token><Token POSTag="IN" id="1">of</Token><Token POSTag="DT" id="2">those</Token><Token POSTag="NNS" id="3">patients</Token><Token POSTag="VBD" id="4">needed</Token><Token POSTag="NN" id="5">dose</Token><Token POSTag="NNS" id="6">reductions</Token><Token POSTag="RB" id="7">afterwards</Token><Token POSTag="JJ" id="8">due</Token><Token POSTag="TO" id="9">to</Token><Token POSTag="JJ" id="10">adverse</Token><Token POSTag="NN" id="11">drug</Token><Token POSTag="NNS" id="12">reactions</Token><Token POSTag="." id="13">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NP (CD Seven)) (PP (IN of) (NP (DT those) (NNS patients)))) (VP (VBD needed) (NP (NN dose) (NNS reductions)) (PP (ADVP (RB afterwards)) (JJ due) (TO to) (NP (JJ adverse) (NN drug) (NNS reactions))))) (. .)))</ParseTree></Sentence><Sentence id="4">Ten patients started with a reduced starting dose (below 50 mg daily, 4/6 weeks).<Tokens Count="18"><Token POSTag="CD" id="0">Ten</Token><Token POSTag="NNS" id="1">patients</Token><Token POSTag="VBD" id="2">started</Token><Token POSTag="IN" id="3">with</Token><Token POSTag="DT" id="4">a</Token><Token POSTag="VBN" id="5">reduced</Token><Token POSTag="VBG" id="6">starting</Token><Token POSTag="NN" id="7">dose</Token><Token POSTag="-LRB-" id="8">(</Token><Token POSTag="IN" id="9">below</Token><Token POSTag="CD" id="10">50</Token><Token POSTag="NN" id="11">mg</Token><Token POSTag="RB" id="12">daily</Token><Token POSTag="," id="13">,</Token><Token POSTag="CD" id="14">4/6</Token><Token POSTag="NNS" id="15">weeks</Token><Token POSTag="-RRB-" id="16">)</Token><Token POSTag="." id="17">.</Token></Tokens><ParseTree>(S1 (S (S (NP (CD Ten) (NNS patients)) (VP (VBD started) (PP (IN with) (NP (NP (DT a) (VBN reduced) (VBG starting) (NN dose)) (PRN (-LRB- -LRB-) (NP (NP (QP (IN below) (CD 50)) (NN mg)) (ADVP (RB daily)) (, ,) (NP (CD 4/6) (NNS weeks))) (-RRB- -RRB-)))))) (. .)))</ParseTree></Sentence><Sentence id="5">The mean age of those patients was 72.7 years (range 64-76 years), and the mean number of comorbidities was 2.0 (range 1-5 comorbidities).<Tokens Count="29"><Token POSTag="DT" id="0">The</Token><Token POSTag="JJ" id="1">mean</Token><Token POSTag="NN" id="2">age</Token><Token POSTag="IN" id="3">of</Token><Token POSTag="DT" id="4">those</Token><Token POSTag="NNS" id="5">patients</Token><Token POSTag="VBD" id="6">was</Token><Token POSTag="CD" id="7">72.7</Token><Token POSTag="NNS" id="8">years</Token><Token POSTag="-LRB-" id="9">(</Token><Token POSTag="NN" id="10">range</Token><Token POSTag="CD" id="11">64-76</Token><Token POSTag="NNS" id="12">years</Token><Token POSTag="-RRB-" id="13">)</Token><Token POSTag="," id="14">,</Token><Token POSTag="CC" id="15">and</Token><Token POSTag="DT" id="16">the</Token><Token POSTag="NN" id="17">mean</Token><Token POSTag="NN" id="18">number</Token><Token POSTag="IN" id="19">of</Token><Token POSTag="NNS" id="20">comorbidities</Token><Token POSTag="VBD" id="21">was</Token><Token POSTag="CD" id="22">2.0</Token><Token POSTag="-LRB-" id="23">(</Token><Token POSTag="NN" id="24">range</Token><Token POSTag="CD" id="25">1-5</Token><Token POSTag="NNS" id="26">comorbidities</Token><Token POSTag="-RRB-" id="27">)</Token><Token POSTag="." id="28">.</Token></Tokens><ParseTree>(S1 (S (S (S (NP (NP (DT The) (JJ mean) (NN age)) (PP (IN of) (NP (DT those) (NNS patients)))) (VP (VBD was) (NP (NP (CD 72.7) (NNS years)) (PRN (-LRB- -LRB-) (NP (NN range) (CD 64-76) (NNS years)) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (NP (DT the) (NN mean) (NN number)) (PP (IN of) (NP (NNS comorbidities)))) (VP (VBD was) (NP (NP (CD 2.0)) (PRN (-LRB- -LRB-) (NP (NN range) (CD 1-5) (NNS comorbidities)) (-RRB- -RRB-)))))) (. .)))</ParseTree></Sentence><Sentence id="6">Five patients needed more dose reduction afterwards due to adverse drug reactions.<Tokens Count="13"><Token POSTag="CD" id="0">Five</Token><Token POSTag="NNS" id="1">patients</Token><Token POSTag="VBD" id="2">needed</Token><Token POSTag="RBR" id="3">more</Token><Token POSTag="NN" id="4">dose</Token><Token POSTag="NN" id="5">reduction</Token><Token POSTag="RB" id="6">afterwards</Token><Token POSTag="JJ" id="7">due</Token><Token POSTag="TO" id="8">to</Token><Token POSTag="JJ" id="9">adverse</Token><Token POSTag="NN" id="10">drug</Token><Token POSTag="NNS" id="11">reactions</Token><Token POSTag="." id="12">.</Token></Tokens><ParseTree>(S1 (S (S (NP (CD Five) (NNS patients)) (VP (VBD needed) (NP (RBR more) (NN dose) (NN reduction)) (PP (ADVP (RB afterwards)) (JJ due) (TO to) (NP (JJ adverse) (NN drug) (NNS reactions))))) (. .)))</ParseTree></Sentence><Sentence id="7">Adverse drug reactions (all grades) in the younger patient population (full starting dose) who needed dose reduction (n = 7) were hypertension, nausea, diarrhoea, hand-foot skin reaction, fatigue, anorexia, taste disturbances, hypothyroidism, skin rash, mucositis and thrombopenia.<Tokens Count="53"><Token POSTag="JJ" id="0">Adverse</Token><Token POSTag="NN" id="1">drug</Token><Token POSTag="NNS" id="2">reactions</Token><Token POSTag="-LRB-" id="3">(</Token><Token POSTag="DT" id="4">all</Token><Token POSTag="NNS" id="5">grades</Token><Token POSTag="-RRB-" id="6">)</Token><Token POSTag="IN" id="7">in</Token><Token POSTag="DT" id="8">the</Token><Token POSTag="JJR" id="9">younger</Token><Token POSTag="NN" id="10">patient</Token><Token POSTag="NN" id="11">population</Token><Token POSTag="-LRB-" id="12">(</Token><Token POSTag="JJ" id="13">full</Token><Token POSTag="VBG" id="14">starting</Token><Token POSTag="NN" id="15">dose</Token><Token POSTag="-RRB-" id="16">)</Token><Token POSTag="WP" id="17">who</Token><Token POSTag="VBN" id="18">needed</Token><Token POSTag="NN" id="19">dose</Token><Token POSTag="NN" id="20">reduction</Token><Token POSTag="-LRB-" id="21">(</Token><Token POSTag="NN" id="22">n</Token><Token POSTag="JJ" id="23">=</Token><Token POSTag="CD" id="24">7</Token><Token POSTag="-RRB-" id="25">)</Token><Token POSTag="VBD" id="26">were</Token><Token POSTag="NN" id="27">hypertension</Token><Token POSTag="," id="28">,</Token><Token POSTag="NN" id="29">nausea</Token><Token POSTag="," id="30">,</Token><Token POSTag="NN" id="31">diarrhoea</Token><Token POSTag="," id="32">,</Token><Token POSTag="JJ" id="33">hand-foot</Token><Token POSTag="NN" id="34">skin</Token><Token POSTag="NN" id="35">reaction</Token><Token POSTag="," id="36">,</Token><Token POSTag="NN" id="37">fatigue</Token><Token POSTag="," id="38">,</Token><Token POSTag="NN" id="39">anorexia</Token><Token POSTag="," id="40">,</Token><Token POSTag="NN" id="41">taste</Token><Token POSTag="NNS" id="42">disturbances</Token><Token POSTag="," id="43">,</Token><Token POSTag="NN" id="44">hypothyroidism</Token><Token POSTag="," id="45">,</Token><Token POSTag="NN" id="46">skin</Token><Token POSTag="NN" id="47">rash</Token><Token POSTag="," id="48">,</Token><Token POSTag="NN" id="49">mucositis</Token><Token POSTag="CC" id="50">and</Token><Token POSTag="NN" id="51">thrombopenia</Token><Token POSTag="." id="52">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NP (NP (JJ Adverse) (NN drug) (NNS reactions)) (PRN (-LRB- -LRB-) (NP (DT all) (NNS grades)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT the) (JJR younger) (NN patient) (NN population)) (PRN (-LRB- -LRB-) (NP (JJ full) (VBG starting) (NN dose)) (-RRB- -RRB-)))) (SBAR (WHNP (WP who)) (S (VP (VBN needed) (NP (NP (NN dose) (NN reduction)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 7)) (-RRB- -RRB-))))))) (VP (VBD were) (NP (NP (NN hypertension)) (, ,) (NP (NP (NN nausea)) (, ,) (NP (NN diarrhoea)) (, ,) (NP (JJ hand-foot) (NN skin) (NN reaction)) (, ,) (NP (NN fatigue)) (, ,) (NP (NN anorexia)) (, ,) (NP (NN taste) (NNS disturbances)) (, ,) (NP (NN hypothyroidism)) (, ,) (NP (NN skin) (NN rash)) (, ,) (NP (NN mucositis)) (CC and) (NP (NN thrombopenia)))))) (. .)))</ParseTree></Sentence><Sentence id="8">Adverse drug reactions (all grades) in the older patient population (reduced starting dose) who needed further dose reduction (n = 4) were nausea, anorexia, taste disturbances, weight loss, diarrhoea, mucositis, pyrosis, hand-foot skin reaction, malaise and conjunctivitis.<Tokens Count="52"><Token POSTag="JJ" id="0">Adverse</Token><Token POSTag="NN" id="1">drug</Token><Token POSTag="NNS" id="2">reactions</Token><Token POSTag="-LRB-" id="3">(</Token><Token POSTag="DT" id="4">all</Token><Token POSTag="NNS" id="5">grades</Token><Token POSTag="-RRB-" id="6">)</Token><Token POSTag="IN" id="7">in</Token><Token POSTag="DT" id="8">the</Token><Token POSTag="JJR" id="9">older</Token><Token POSTag="NN" id="10">patient</Token><Token POSTag="NN" id="11">population</Token><Token POSTag="-LRB-" id="12">(</Token><Token POSTag="VBN" id="13">reduced</Token><Token POSTag="VBG" id="14">starting</Token><Token POSTag="NN" id="15">dose</Token><Token POSTag="-RRB-" id="16">)</Token><Token POSTag="WP" id="17">who</Token><Token POSTag="VBN" id="18">needed</Token><Token POSTag="JJ" id="19">further</Token><Token POSTag="NN" id="20">dose</Token><Token POSTag="NN" id="21">reduction</Token><Token POSTag="-LRB-" id="22">(</Token><Token POSTag="NN" id="23">n</Token><Token POSTag="JJ" id="24">=</Token><Token POSTag="CD" id="25">4</Token><Token POSTag="-RRB-" id="26">)</Token><Token POSTag="VBD" id="27">were</Token><Token POSTag="NN" id="28">nausea</Token><Token POSTag="," id="29">,</Token><Token POSTag="NN" id="30">anorexia</Token><Token POSTag="," id="31">,</Token><Token POSTag="NN" id="32">taste</Token><Token POSTag="NNS" id="33">disturbances</Token><Token POSTag="," id="34">,</Token><Token POSTag="NN" id="35">weight</Token><Token POSTag="NN" id="36">loss</Token><Token POSTag="," id="37">,</Token><Token POSTag="NN" id="38">diarrhoea</Token><Token POSTag="," id="39">,</Token><Token POSTag="NN" id="40">mucositis</Token><Token POSTag="," id="41">,</Token><Token POSTag="NN" id="42">pyrosis</Token><Token POSTag="," id="43">,</Token><Token POSTag="JJ" id="44">hand-foot</Token><Token POSTag="NN" id="45">skin</Token><Token POSTag="NN" id="46">reaction</Token><Token POSTag="," id="47">,</Token><Token POSTag="NN" id="48">malaise</Token><Token POSTag="CC" id="49">and</Token><Token POSTag="NN" id="50">conjunctivitis</Token><Token POSTag="." id="51">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NP (NP (JJ Adverse) (NN drug) (NNS reactions)) (PRN (-LRB- -LRB-) (NP (DT all) (NNS grades)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT the) (JJR older) (NN patient) (NN population)) (PRN (-LRB- -LRB-) (NP (VBN reduced) (VBG starting) (NN dose)) (-RRB- -RRB-)))) (SBAR (WHNP (WP who)) (S (VP (VBN needed) (NP (NP (JJ further) (NN dose) (NN reduction)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 4)) (-RRB- -RRB-))))))) (VP (VBD were) (NP (NP (NN nausea)) (, ,) (NP (NN anorexia)) (, ,) (NP (NN taste) (NNS disturbances)) (, ,) (NP (NN weight) (NN loss)) (, ,) (NP (NN diarrhoea)) (, ,) (NP (NN mucositis)) (, ,) (NP (NN pyrosis)) (, ,) (NP (JJ hand-foot) (NN skin) (NN reaction)) (, ,) (NP (NN malaise)) (CC and) (NP (NN conjunctivitis))))) (. .)))</ParseTree></Sentence><Sentence id="9">Twenty-two percentage of the patients needed thyroid substitution therapy, whereas 31% of the patients were prescribed anti-emetics, most frequently domperidone followed by metoclopramide and alizapride.<Tokens Count="29"><Token POSTag="CD" id="0">Twenty-two</Token><Token POSTag="NN" id="1">percentage</Token><Token POSTag="IN" id="2">of</Token><Token POSTag="DT" id="3">the</Token><Token POSTag="NNS" id="4">patients</Token><Token POSTag="VBD" id="5">needed</Token><Token POSTag="NN" id="6">thyroid</Token><Token POSTag="NN" id="7">substitution</Token><Token POSTag="NN" id="8">therapy</Token><Token POSTag="," id="9">,</Token><Token POSTag="IN" id="10">whereas</Token><Token POSTag="CD" id="11">31</Token><Token POSTag="NN" id="12">%</Token><Token POSTag="IN" id="13">of</Token><Token POSTag="DT" id="14">the</Token><Token POSTag="NNS" id="15">patients</Token><Token POSTag="VBD" id="16">were</Token><Token POSTag="VBN" id="17">prescribed</Token><Token POSTag="NN" id="18">anti-emetics</Token><Token POSTag="," id="19">,</Token><Token POSTag="RBS" id="20">most</Token><Token POSTag="RB" id="21">frequently</Token><Token POSTag="NN" id="22">domperidone</Token><Token POSTag="VBN" id="23">followed</Token><Token POSTag="IN" id="24">by</Token><Token POSTag="NN" id="25">metoclopramide</Token><Token POSTag="CC" id="26">and</Token><Token POSTag="NN" id="27">alizapride</Token><Token POSTag="." id="28">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NP (CD Twenty-two) (NN percentage)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD needed) (NP (NN thyroid) (NN substitution) (NN therapy)) (, ,) (SBAR (IN whereas) (S (NP (NP (CD 31) (NN %)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD were) (VP (VBN prescribed) (NP (NN anti-emetics)))))) (, ,) (ADVP (RBS most) (RB frequently)) (S (NP (NN domperidone)) (VP (VBN followed) (PP (IN by) (NP (NP (NN metoclopramide)) (CC and) (NP (NN alizapride)))))))) (. .)))</ParseTree></Sentence><Sentence id="10">Diarrhoea (all grades) was reported in 19% of all cases.<Tokens Count="14"><Token POSTag="NN" id="0">Diarrhoea</Token><Token POSTag="-LRB-" id="1">(</Token><Token POSTag="DT" id="2">all</Token><Token POSTag="NNS" id="3">grades</Token><Token POSTag="-RRB-" id="4">)</Token><Token POSTag="VBD" id="5">was</Token><Token POSTag="VBN" id="6">reported</Token><Token POSTag="IN" id="7">in</Token><Token POSTag="CD" id="8">19</Token><Token POSTag="NN" id="9">%</Token><Token POSTag="IN" id="10">of</Token><Token POSTag="DT" id="11">all</Token><Token POSTag="NNS" id="12">cases</Token><Token POSTag="." id="13">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NP (NN Diarrhoea)) (PRN (-LRB- -LRB-) (NP (DT all) (NNS grades)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN reported) (PP (IN in) (NP (NP (CD 19) (NN %)) (PP (IN of) (NP (DT all) (NNS cases)))))))) (. .)))</ParseTree></Sentence><Sentence id="11">Eleven percentage of the patients were prescribed loperamide. <Tokens Count="9"><Token POSTag="CD" id="0">Eleven</Token><Token POSTag="NN" id="1">percentage</Token><Token POSTag="IN" id="2">of</Token><Token POSTag="DT" id="3">the</Token><Token POSTag="NNS" id="4">patients</Token><Token POSTag="VBD" id="5">were</Token><Token POSTag="VBN" id="6">prescribed</Token><Token POSTag="NN" id="7">loperamide</Token><Token POSTag="." id="8">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NP (CD Eleven) (NN percentage)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD were) (VP (VBN prescribed) (NP (NN loperamide))))) (. .)))</ParseTree></Sentence></Sentences></Paragraph><Paragraph id="5"><Sentences Count="4"><Sentence id="0">Regarding the role of possible drug-drug interactions between the prescribed comedication and sunitinib, a possible pharmacodynamic interaction causing QT prolongation was most common.<Tokens Count="25"><Token POSTag="VBG" id="0">Regarding</Token><Token POSTag="DT" id="1">the</Token><Token POSTag="NN" id="2">role</Token><Token POSTag="IN" id="3">of</Token><Token POSTag="JJ" id="4">possible</Token><Token POSTag="JJ" id="5">drug-drug</Token><Token POSTag="NNS" id="6">interactions</Token><Token POSTag="IN" id="7">between</Token><Token POSTag="DT" id="8">the</Token><Token POSTag="VBN" id="9">prescribed</Token><Token POSTag="NN" id="10">comedication</Token><Token POSTag="CC" id="11">and</Token><Token POSTag="NN" id="12">sunitinib</Token><Token POSTag="," id="13">,</Token><Token POSTag="DT" id="14">a</Token><Token POSTag="JJ" id="15">possible</Token><Token POSTag="JJ" id="16">pharmacodynamic</Token><Token POSTag="NN" id="17">interaction</Token><Token POSTag="VBG" id="18">causing</Token><Token POSTag="NN" id="19">QT</Token><Token POSTag="NN" id="20">prolongation</Token><Token POSTag="VBD" id="21">was</Token><Token POSTag="RBS" id="22">most</Token><Token POSTag="JJ" id="23">common</Token><Token POSTag="." id="24">.</Token></Tokens><ParseTree>(S1 (S (S (PP (VBG Regarding) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (JJ possible) (JJ drug-drug) (NNS interactions)) (PP (IN between) (NP (NP (DT the) (VBN prescribed) (NN comedication)) (CC and) (NP (NN sunitinib)))))))) (, ,) (NP (NP (DT a) (JJ possible) (JJ pharmacodynamic) (NN interaction)) (VP (VBG causing) (NP (NN QT) (NN prolongation)))) (VP (VBD was) (ADJP (RBS most) (JJ common)))) (. .)))</ParseTree></Sentence><Sentence id="1">In 44% of all cases, this could have caused a major or moderate interaction depending on the database used.<Tokens Count="22"><Token POSTag="IN" id="0">In</Token><Token POSTag="CD" id="1">44</Token><Token POSTag="NN" id="2">%</Token><Token POSTag="IN" id="3">of</Token><Token POSTag="DT" id="4">all</Token><Token POSTag="NNS" id="5">cases</Token><Token POSTag="," id="6">,</Token><Token POSTag="DT" id="7">this</Token><Token POSTag="MD" id="8">could</Token><Token POSTag="VB" id="9">have</Token><Token POSTag="VBD" id="10">caused</Token><Token POSTag="DT" id="11">a</Token><Token POSTag="JJ" id="12">major</Token><Token POSTag="CC" id="13">or</Token><Token POSTag="JJ" id="14">moderate</Token><Token POSTag="NN" id="15">interaction</Token><Token POSTag="VBG" id="16">depending</Token><Token POSTag="IN" id="17">on</Token><Token POSTag="DT" id="18">the</Token><Token POSTag="NN" id="19">database</Token><Token POSTag="VBN" id="20">used</Token><Token POSTag="." id="21">.</Token></Tokens><ParseTree>(S1 (S (S (PP (IN In) (NP (NP (CD 44) (NN %)) (PP (IN of) (NP (DT all) (NNS cases))))) (, ,) (NP (DT this)) (VP (MD could) (VP (VB have) (VP (VBD caused) (NP (DT a) (ADJP (ADJP (JJ major)) (CC or) (ADJP (JJ moderate))) (NN interaction)) (PP (VBG depending) (PP (IN on) (NP (NP (DT the) (NN database)) (VP (VBN used))))))))) (. .)))</ParseTree></Sentence><Sentence id="2">The prescribed drugs prone to QT prolongation were domperidone and loperamide.<Tokens Count="12"><Token POSTag="DT" id="0">The</Token><Token POSTag="VBN" id="1">prescribed</Token><Token POSTag="NNS" id="2">drugs</Token><Token POSTag="JJ" id="3">prone</Token><Token POSTag="TO" id="4">to</Token><Token POSTag="NN" id="5">QT</Token><Token POSTag="NN" id="6">prolongation</Token><Token POSTag="VBD" id="7">were</Token><Token POSTag="NN" id="8">domperidone</Token><Token POSTag="CC" id="9">and</Token><Token POSTag="NN" id="10">loperamide</Token><Token POSTag="." id="11">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NP (DT The) (VBN prescribed) (NNS drugs)) (ADJP (JJ prone) (PP (TO to) (NP (NN QT) (NN prolongation))))) (VP (VBD were) (NP (NP (NN domperidone)) (CC and) (NP (NN loperamide))))) (. .)))</ParseTree></Sentence><Sentence id="3">Although no routinely ECG monitoring was performed in this retrospective cohort of patients, no major ventricular arrhythmias or sudden deaths were seen. <Tokens Count="24"><Token POSTag="IN" id="0">Although</Token><Token POSTag="DT" id="1">no</Token><Token POSTag="RB" id="2">routinely</Token><Token POSTag="NN" id="3">ECG</Token><Token POSTag="NN" id="4">monitoring</Token><Token POSTag="VBD" id="5">was</Token><Token POSTag="VBN" id="6">performed</Token><Token POSTag="IN" id="7">in</Token><Token POSTag="DT" id="8">this</Token><Token POSTag="JJ" id="9">retrospective</Token><Token POSTag="NN" id="10">cohort</Token><Token POSTag="IN" id="11">of</Token><Token POSTag="NNS" id="12">patients</Token><Token POSTag="," id="13">,</Token><Token POSTag="DT" id="14">no</Token><Token POSTag="JJ" id="15">major</Token><Token POSTag="JJ" id="16">ventricular</Token><Token POSTag="NNS" id="17">arrhythmias</Token><Token POSTag="CC" id="18">or</Token><Token POSTag="JJ" id="19">sudden</Token><Token POSTag="NNS" id="20">deaths</Token><Token POSTag="VBD" id="21">were</Token><Token POSTag="VBN" id="22">seen</Token><Token POSTag="." id="23">.</Token></Tokens><ParseTree>(S1 (S (S (SBAR (IN Although) (S (NP (DT no) (RB routinely) (NN ECG) (NN monitoring)) (VP (VBD was) (VP (VBN performed) (PP (IN in) (NP (NP (DT this) (JJ retrospective) (NN cohort)) (PP (IN of) (NP (NNS patients))))))))) (, ,) (NP (NP (DT no) (JJ major) (JJ ventricular) (NNS arrhythmias)) (CC or) (NP (JJ sudden) (NNS deaths))) (VP (VBD were) (VP (VBN seen)))) (. .)))</ParseTree></Sentence></Sentences></Paragraph><Paragraph id="6"><Sentences Count="2"><Sentence id="0">The role of pharmacokinetic interactions seemed to be less important.<Tokens Count="11"><Token POSTag="DT" id="0">The</Token><Token POSTag="NN" id="1">role</Token><Token POSTag="IN" id="2">of</Token><Token POSTag="JJ" id="3">pharmacokinetic</Token><Token POSTag="NNS" id="4">interactions</Token><Token POSTag="VBD" id="5">seemed</Token><Token POSTag="TO" id="6">to</Token><Token POSTag="VB" id="7">be</Token><Token POSTag="RBR" id="8">less</Token><Token POSTag="JJ" id="9">important</Token><Token POSTag="." id="10">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (JJ pharmacokinetic) (NNS interactions)))) (VP (VBD seemed) (S (VP (TO to) (VP (VB be) (ADJP (RBR less) (JJ important))))))) (. .)))</ParseTree></Sentence><Sentence id="1">The data revealed only 3 possible interactions with a CYP inhibitor and 4 possible interactions with a CYP inducer.<Tokens Count="20"><Token POSTag="DT" id="0">The</Token><Token POSTag="NNS" id="1">data</Token><Token POSTag="VBD" id="2">revealed</Token><Token POSTag="RB" id="3">only</Token><Token POSTag="CD" id="4">3</Token><Token POSTag="JJ" id="5">possible</Token><Token POSTag="NNS" id="6">interactions</Token><Token POSTag="IN" id="7">with</Token><Token POSTag="DT" id="8">a</Token><Token POSTag="NN" id="9">CYP</Token><Token POSTag="NN" id="10">inhibitor</Token><Token POSTag="CC" id="11">and</Token><Token POSTag="CD" id="12">4</Token><Token POSTag="JJ" id="13">possible</Token><Token POSTag="NNS" id="14">interactions</Token><Token POSTag="IN" id="15">with</Token><Token POSTag="DT" id="16">a</Token><Token POSTag="JJ" id="17">CYP</Token><Token POSTag="NN" id="18">inducer</Token><Token POSTag="." id="19">.</Token></Tokens><ParseTree>(S1 (S (S (NP (DT The) (NNS data)) (VP (VBD revealed) (NP (NP (NP (QP (RB only) (CD 3)) (JJ possible) (NNS interactions)) (PP (IN with) (NP (DT a) (NN CYP) (NN inhibitor)))) (CC and) (NP (NP (CD 4) (JJ possible) (NNS interactions)) (PP (IN with) (NP (DT a) (JJ CYP) (NN inducer))))))) (. .)))</ParseTree></Sentence></Sentences></Paragraph><Paragraph id="7"><Sentences Count="2"><Sentence id="0">The subpopulation of patients taking a CYP inhibitor or inducer was prescribed an important amount of comedications (number ranging from 4 to 13), and this subgroup had a PFS ranging from 25 to 557 days.<Tokens Count="39"><Token POSTag="DT" id="0">The</Token><Token POSTag="NN" id="1">subpopulation</Token><Token POSTag="IN" id="2">of</Token><Token POSTag="NNS" id="3">patients</Token><Token POSTag="VBG" id="4">taking</Token><Token POSTag="DT" id="5">a</Token><Token POSTag="NN" id="6">CYP</Token><Token POSTag="NN" id="7">inhibitor</Token><Token POSTag="CC" id="8">or</Token><Token POSTag="NN" id="9">inducer</Token><Token POSTag="VBD" id="10">was</Token><Token POSTag="VBN" id="11">prescribed</Token><Token POSTag="DT" id="12">an</Token><Token POSTag="JJ" id="13">important</Token><Token POSTag="NN" id="14">amount</Token><Token POSTag="IN" id="15">of</Token><Token POSTag="NNS" id="16">comedications</Token><Token POSTag="-LRB-" id="17">(</Token><Token POSTag="NN" id="18">number</Token><Token POSTag="VBG" id="19">ranging</Token><Token POSTag="IN" id="20">from</Token><Token POSTag="CD" id="21">4</Token><Token POSTag="TO" id="22">to</Token><Token POSTag="CD" id="23">13</Token><Token POSTag="-RRB-" id="24">)</Token><Token POSTag="," id="25">,</Token><Token POSTag="CC" id="26">and</Token><Token POSTag="DT" id="27">this</Token><Token POSTag="NN" id="28">subgroup</Token><Token POSTag="VBD" id="29">had</Token><Token POSTag="DT" id="30">a</Token><Token POSTag="NN" id="31">PFS</Token><Token POSTag="VBG" id="32">ranging</Token><Token POSTag="IN" id="33">from</Token><Token POSTag="CD" id="34">25</Token><Token POSTag="TO" id="35">to</Token><Token POSTag="CD" id="36">557</Token><Token POSTag="NNS" id="37">days</Token><Token POSTag="." id="38">.</Token></Tokens><ParseTree>(S1 (S (S (S (NP (NP (DT The) (NN subpopulation)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (DT a) (NN CYP) (NN inhibitor)) (CC or) (NP (NN inducer))))))) (VP (VBD was) (VP (VBN prescribed) (NP (NP (DT an) (JJ important) (NN amount)) (PP (IN of) (NP (NP (NNS comedications)) (PRN (-LRB- -LRB-) (NP (NP (NN number)) (VP (VBG ranging) (PP (IN from) (NP (CD 4) (TO to) (CD 13))))) (-RRB- -RRB-)))))))) (, ,) (CC and) (S (NP (DT this) (NN subgroup)) (VP (VBD had) (NP (NP (DT a) (NN PFS)) (VP (VBG ranging) (PP (IN from) (NP (QP (CD 25) (TO to) (CD 557)) (NNS days)))))))) (. .)))</ParseTree></Sentence><Sentence id="1">Outcome was not different from the whole population studied. <Tokens Count="10"><Token POSTag="NN" id="0">Outcome</Token><Token POSTag="VBD" id="1">was</Token><Token POSTag="RB" id="2">not</Token><Token POSTag="JJ" id="3">different</Token><Token POSTag="IN" id="4">from</Token><Token POSTag="DT" id="5">the</Token><Token POSTag="JJ" id="6">whole</Token><Token POSTag="NN" id="7">population</Token><Token POSTag="VBN" id="8">studied</Token><Token POSTag="." id="9">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NN Outcome)) (VP (VBD was) (RB not) (ADJP (JJ different) (PP (IN from) (NP (NP (DT the) (JJ whole) (NN population)) (VP (VBN studied))))))) (. .)))</ParseTree></Sentence></Sentences></Paragraph><Paragraph id="8"><Sentences Count="2"><Sentence id="0">Several patients were prescribed medication causing a possible interaction with a P-glycoprotein (PgP) substrate.<Tokens Count="17"><Token POSTag="JJ" id="0">Several</Token><Token POSTag="NNS" id="1">patients</Token><Token POSTag="VBD" id="2">were</Token><Token POSTag="VBN" id="3">prescribed</Token><Token POSTag="NN" id="4">medication</Token><Token POSTag="VBG" id="5">causing</Token><Token POSTag="DT" id="6">a</Token><Token POSTag="JJ" id="7">possible</Token><Token POSTag="NN" id="8">interaction</Token><Token POSTag="IN" id="9">with</Token><Token POSTag="DT" id="10">a</Token><Token POSTag="NN" id="11">P-glycoprotein</Token><Token POSTag="-LRB-" id="12">(</Token><Token POSTag="NN" id="13">PgP</Token><Token POSTag="-RRB-" id="14">)</Token><Token POSTag="NN" id="15">substrate</Token><Token POSTag="." id="16">.</Token></Tokens><ParseTree>(S1 (S (S (NP (JJ Several) (NNS patients)) (VP (VBD were) (VP (VBN prescribed) (NP (NP (NN medication)) (VP (VBG causing) (NP (NP (DT a) (JJ possible) (NN interaction)) (PP (IN with) (NP (DT a) (NN P-glycoprotein) (-LRB- -LRB-) (NN PgP) (-RRB- -RRB-) (NN substrate))))))))) (. .)))</ParseTree></Sentence><Sentence id="1">According to the data, the concomitant use of another PgP substrate causes a moderate or major interaction depending on the database used. <Tokens Count="24"><Token POSTag="VBG" id="0">According</Token><Token POSTag="TO" id="1">to</Token><Token POSTag="DT" id="2">the</Token><Token POSTag="NNS" id="3">data</Token><Token POSTag="," id="4">,</Token><Token POSTag="DT" id="5">the</Token><Token POSTag="JJ" id="6">concomitant</Token><Token POSTag="NN" id="7">use</Token><Token POSTag="IN" id="8">of</Token><Token POSTag="DT" id="9">another</Token><Token POSTag="JJ" id="10">PgP</Token><Token POSTag="NN" id="11">substrate</Token><Token POSTag="VBZ" id="12">causes</Token><Token POSTag="DT" id="13">a</Token><Token POSTag="JJ" id="14">moderate</Token><Token POSTag="CC" id="15">or</Token><Token POSTag="JJ" id="16">major</Token><Token POSTag="NN" id="17">interaction</Token><Token POSTag="VBG" id="18">depending</Token><Token POSTag="IN" id="19">on</Token><Token POSTag="DT" id="20">the</Token><Token POSTag="NN" id="21">database</Token><Token POSTag="VBN" id="22">used</Token><Token POSTag="." id="23">.</Token></Tokens><ParseTree>(S1 (S (S (S (VP (VBG According) (PP (TO to) (NP (DT the) (NNS data))))) (, ,) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (DT another) (JJ PgP) (NN substrate)))) (VP (VBZ causes) (NP (DT a) (ADJP (ADJP (JJ moderate)) (CC or) (ADJP (JJ major))) (NN interaction)) (PP (VBG depending) (PP (IN on) (NP (NP (DT the) (NN database)) (VP (VBN used))))))) (. .)))</ParseTree></Sentence></Sentences></Paragraph><Paragraph id="9"><Sentences Count="3"><Sentence id="0">A patient received sunitinib malate and developed a drug interaction (QT prolongation).<Tokens Count="15"><Token POSTag="DT" id="0">A</Token><Token POSTag="NN" id="1">patient</Token><Token POSTag="VBD" id="2">received</Token><Token POSTag="NN" id="3">sunitinib</Token><Token POSTag="NN" id="4">malate</Token><Token POSTag="CC" id="5">and</Token><Token POSTag="VBD" id="6">developed</Token><Token POSTag="DT" id="7">a</Token><Token POSTag="NN" id="8">drug</Token><Token POSTag="NN" id="9">interaction</Token><Token POSTag="-LRB-" id="10">(</Token><Token POSTag="NN" id="11">QT</Token><Token POSTag="NN" id="12">prolongation</Token><Token POSTag="-RRB-" id="13">)</Token><Token POSTag="." id="14">.</Token></Tokens><ParseTree>(S1 (S (S (NP (DT A) (NN patient)) (VP (VP (VBD received) (NP (NN sunitinib) (NN malate))) (CC and) (VP (VBD developed) (NP (NP (DT a) (NN drug) (NN interaction)) (PRN (-LRB- -LRB-) (NP (NN QT) (NN prolongation)) (-RRB- -RRB-)))))) (. .)))</ParseTree></Sentence><Sentence id="1">The comedication causing interaction with sunitinib was domperidone (an anti-emetic).<Tokens Count="13"><Token POSTag="DT" id="0">The</Token><Token POSTag="JJ" id="1">comedication</Token><Token POSTag="VBG" id="2">causing</Token><Token POSTag="NN" id="3">interaction</Token><Token POSTag="IN" id="4">with</Token><Token POSTag="NN" id="5">sunitinib</Token><Token POSTag="VBD" id="6">was</Token><Token POSTag="NN" id="7">domperidone</Token><Token POSTag="-LRB-" id="8">(</Token><Token POSTag="DT" id="9">an</Token><Token POSTag="JJ" id="10">anti-emetic</Token><Token POSTag="-RRB-" id="11">)</Token><Token POSTag="." id="12">.</Token></Tokens><ParseTree>(S1 (S (S (NP (NP (DT The) (JJ comedication) (VBG causing) (NN interaction)) (PP (IN with) (NP (NN sunitinib)))) (VP (VBD was) (NP (NN domperidone)) (PRN (-LRB- -LRB-) (NP (DT an) (JJ anti-emetic)) (-RRB- -RRB-)))) (. .)))</ParseTree></Sentence><Sentence id="2">Concomitant medication included methylprednisolone and alprazolam.<Tokens Count="7"><Token POSTag="JJ" id="0">Concomitant</Token><Token POSTag="NN" id="1">medication</Token><Token POSTag="VBD" id="2">included</Token><Token POSTag="NN" id="3">methylprednisolone</Token><Token POSTag="CC" id="4">and</Token><Token POSTag="NN" id="5">alprazolam</Token><Token POSTag="." id="6">.</Token></Tokens><ParseTree>(S1 (S (S (NP (JJ Concomitant) (NN medication)) (VP (VBD included) (NP (NP (NN methylprednisolone)) (CC and) (NP (NN alprazolam))))) (. .)))</ParseTree></Sentence></Sentences></Paragraph></Paragraphs></StartOutput>